Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz' Biosimilar Etanercept On Its Way To EU Market

This article was originally published in Scrip

Executive Summary

The EMA has accepted for review a biosimilar etanercept product from Novartis's Sandoz division. The biosimilar version of Pfizer's TNF-inhibitor Enbrel has been filed for use in all the indications detailed in Enbrel's label, including rheumatoid arthritis and psoriasis.

Advertisement

Related Content

Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing

Topics

Advertisement
UsernamePublicRestriction

Register

SC063927

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel